Author: Vikas Kumar
02 September 2021
Aerosol Therapy Market is expected to exceed the market valuation of more than US$ XX billion by 2027 expanding at a reasonable CAGR of around XX% during the forecast period (2021-2027). One of the cornerstones of respiratory therapy is aerosol therapy. The only healthcare providers who receive formal education in aerosol therapy are respiratory therapists. Bronchodilators can range from short acting to long acting. There are also corticosteroids bronchodilators, combination drugs bronchodilators, mucoactive drugs bronchodilators and others. Some aerosol drugs are present is more than one formulation, whereas the newer drugs are usually present in a single formulation.
There are three common types of aerosol generators for inhaled drug deliver: the pressurized metered-dose inhaler (pMDI), the small volume nebulizer (SVN), and the dry-powder inhaler (DPI). Small volume nebulizers convert liquid drug or suspensions into aerosols. pMDI are small, portable, and self-contained drug device combinations that dispenses multiple doses by a metered value. Lastly, DPI is a device that delivers drug in a powdered form usually with a breadth actuated dosing system. With these clinical aerosol delivery systems, lung deposition may range from 1-50%.
For a detailed analysis of the market drivers in Aerosol Therapy Market browse through – https://univdatos.com/report/aerosol-therapy-market
The recent covid-19 pandemic in 2019 took the world by a storm. The pandemic brought the world to a standstill. All industries have suffered some form of loss due to the pandemic. In addition to this the pandemic has also cost many lives. Till date there have been 177,470,620 covid-19 cases in the world and 3,839,931 deaths. Most nations around the world were affected by the pandemic which not only took lives but also took away jobs. The pandemic caused a huge economic burden all around the world with most industries bearing some form of loss. The Aerosol Therapys industry also saw a slowdown during the pandemic as the industries were shut and production of affected.
Based on product, the aerosol therapy market can be segmented into dry powder inhalers, metered dose inhalers and nebulizers. These segments can then further be sub segmented into single dose inhalers and multi dose inhalers of dry powder inhalers; conventional pressurized inhalers and soft mist inhalers of metered dose inhalers; and jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers of nebulizers. The nebulizers segment had the highest CAGR in the forecasted period on account of its ability of use in all age groups. In the past few years various types of nebulizers have been introduced. Jet nebulizers are most used in patients with pulmonary diseases as they are bulky and work only with a power source.
For a detailed analysis of the Application in the Aerosol Therapy Market browse through – https://univdatos.com/report/aerosol-therapy-market
Based on application, the aerosol therapy market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases, which include diabetes, analgesia and parkinson’s disease. Asthma and COPD are the most treated disorders with aerosol therapy. The asthma segment had the highest CAGR value in the application segment. Asthma is highly prevalent around the world and effect 262 million people in 2019. Asthma is a long-term condition where the air passages in the lungs are partially blocked due to inflammation and muscle tightening. Symptoms of asthma include wheeze, cough, shortness of breadth and tightness in chest.
Based on end-user, the aerosol therapy market is segmented into hospitals, clinics, ambulatory surgical centers, and individuals. The most common end-users are hospitals and individuals. Every year there are approximately 800,000 hospitalizations for Chronic obstructive pulmonary disease (COPD) in the United States which is the third leading cause of death in the country. Additionally, 500,000 hospitalizations for asthma occur yearly and effects about 24 million Americans. Treatments for both COPD and asthma have similar protocols which have been well established over the years. Asthma patients receive inhaled drugs like albuterol and ipratropium.
Request for Sample of the report browse through – https://univdatos.com/request_form/form/456
Additionally, the report provides detailed initiatives that are being taken in the field of Aerosol Therapy, globally. The report provide a detailed analysis of regions including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), and the Rest of the World. North America dominated the market in 2020, with XX% share. Merck, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceuticals, Opko Health, Omron Healthcare, Medtronic, and GE Healthcare are some of the prominent players operating in the global Aerosol Therapy market. Several M&As along with partnerships have been undertaken by these players to make Aerosol Therapys as cost-effective and as widely available as possible.
Aerosol Therapy Market Segmentation
Market Insight, by Product
Market Insight, by Application
Market Insight, by End-User
Market Insight, by Region
Top Company Profiles
Get a call back